<code id='ECF646A19B'></code><style id='ECF646A19B'></style>
    • <acronym id='ECF646A19B'></acronym>
      <center id='ECF646A19B'><center id='ECF646A19B'><tfoot id='ECF646A19B'></tfoot></center><abbr id='ECF646A19B'><dir id='ECF646A19B'><tfoot id='ECF646A19B'></tfoot><noframes id='ECF646A19B'>

    • <optgroup id='ECF646A19B'><strike id='ECF646A19B'><sup id='ECF646A19B'></sup></strike><code id='ECF646A19B'></code></optgroup>
        1. <b id='ECF646A19B'><label id='ECF646A19B'><select id='ECF646A19B'><dt id='ECF646A19B'><span id='ECF646A19B'></span></dt></select></label></b><u id='ECF646A19B'></u>
          <i id='ECF646A19B'><strike id='ECF646A19B'><tt id='ECF646A19B'><pre id='ECF646A19B'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:27
          foreign-trained health professionals
          Adobe

          The pharmaceutical industry has been up in arms over Medicare’s first list of 10 prescription drugs that will be subject to negotiations. But other major parts of the health care industry — hospitals, doctors, and other providers — have refrained from either lending support or criticizing the government’s process.

          The American Hospital Association, the industry’s main lobbying group, told STAT it is “not commenting on this issue right now.” The American Medical Association had no comment and deferred to other physician trade groups. The Federation of American Hospitals offered no statement.

          advertisement

          The American Health Care Association, which lobbies on behalf of nursing homes, did not comment on the list of 10 drugs or Medicare’s negotiating power. But it said in a statement that “many nursing home residents have multiple chronic conditions that require several medications, so any efforts at reducing their out-of-pocket costs would be welcome.”

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          BioMarin wins approval for gene therapy to treat hemophilia A
          BioMarin wins approval for gene therapy to treat hemophilia A

          AdobeTheFoodandDrugAdministrationonThursdayapprovedagenetherapytotreatpeoplewithhemophiliaA,aninheri

          read more
          Biogen walks away from Aduhelm, years after polarizing approval
          Biogen walks away from Aduhelm, years after polarizing approval

          JessicaRinaldi/TheBostonGlobeBiogenisgivingupitsownershipofAduhelm,theAlzheimer’sdiseasetreatmentwho

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Hospitals look to new technology to keep health care workers safe

          AdobeOnedayinearly2020,justweeksbeforePhiladelphiaenteredlockdown,ThomasJeffersonUniversity’spublics